US 11,986,490 B2
Compositions for and method of treating acid-base disorders
Gerrit Klaerner, Hillsborough, CA (US); Jerry M. Buysse, Los Altos, CA (US); Jun Shao, Fremont, CA (US); and Dawn Parsell Otto, Cedar Park, TX (US)
Assigned to Renosis, Inc., Southlake, TX (US)
Filed by Renosis, Inc., Southlake, TX (US)
Filed on Feb. 23, 2022, as Appl. No. 17/678,303.
Application 17/678,303 is a continuation of application No. 16/756,721, granted, now 11,266,684, previously published as PCT/US2018/059092, filed on Nov. 3, 2018.
Claims priority of provisional application 62/748,371, filed on Oct. 19, 2018.
Claims priority of provisional application 62/581,325, filed on Nov. 3, 2017.
Prior Publication US 2023/0031665 A1, Feb. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/785 (2006.01); C08F 226/02 (2006.01)
CPC A61K 31/785 (2013.01) [C08F 226/02 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A method of treating a patient with chronic kidney disease and eubicarbonatemic metabolic acidosis, wherein the method comprises oral administration of a nonabsorbable pharmaceutical composition comprising a proton-binding, crosslinked amine polymer comprising the residue of an amine corresponding to Formula 1:

OG Complex Work Unit Chemistry
wherein R1, R2 and R3 are independently hydrogen, hydrocarbyl, substituted hydrocarbyl provided, however, at least one of R1, R2 and R3 is other than hydrogen, the crosslinked amine polymer has an equilibrium swelling ratio in deionized water of about 5 or less, and the crosslinked amine polymer binds a molar ratio of chloride ions to interfering ions of at least 0.35:1, respectively, in an interfering ion buffer at 37° C. wherein (i) the interfering ions are phosphate ions and the interfering ion buffer is a buffered solution at pH 5.5 of 36 mM chloride and 20 mM phosphate or (ii) the interfering ions are phosphate, citrate and taurocholate ions (combined amount) and the interfering ion buffer is a buffered solution at pH 6.2 including 36 mM chloride, 7 mM phosphate, 1.5 mM citrate, and 5 mM taurocholate.